China Medical (fka CMEDQ)

[peewee]

China Medical Technologies Announces Shareholder Resolution Adopted at its Annual General Meeting Held on November 16, 2009
Date : 11/17/2009 @ 7:00AM
Source : PR Newswire
Stock : China Medical Technologies - Ads (MM) (CMED)
Quote : 15.2099 0.0099 (0.07%) @ 7:22AM


China Medical Technologies Announces Shareholder Resolution Adopted at its Annual General Meeting Held on November 16, 2009





BEIJING, Nov. 17 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (NASDAQ:CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced shareholder resolution adopted at its annual general meeting of shareholders held in Beijing on November 16, 2009.

At the annual general meeting, the Company's shareholders approved the China Medical Technologies, Inc. 2009 Equity Incentive Plan (the "2009 Plan") as adopted by the Company's board of directors and proposed for shareholders' approval by the Company. The terms of the 2009 Plan can be found in the Company's Form 6-K furnished to the U.S. Securities and Exchange Commission (the "SEC") on November 17, 2009, which can be accessed on the Company's Investor Relations website at http://ir.chinameditech.com/ and on the SEC's website at http://www.sec.gov/ . The Company's shareholders did not adopt any other resolution at the annual general meeting.

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic (IVD) products using Enhanced Chemiluminescence (ECLIA) technology, Fluorescent in situ Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology to detect and monitor various diseases and disorders. For more information, please visit http://www.chinameditech.com/ .

For more information, please contact:

Winnie Yam Tel: [phone] Email:

DATASOURCE: China Medical Technologies, Inc.


CONTACT: Winnie Yam, [phone],


Web site: http://www.chinameditech.com/

[peewee]

China Medical Technologies Receives SFDA Approval for its Leukemia BCR/ABL Fusion Gene Detection FISH Probe
Date : 11/09/2009 @ 7:00AM
Source : PR Newswire
Stock : (CMED)
Quote : 15.23 0.21 (1.40%) @ 11:35AM


China Medical Technologies Receives SFDA Approval for its Leukemia BCR/ABL Fusion Gene Detection FISH Probe





BEIJING, Nov. 9 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (NASDAQ:CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its Leukemia BCR/ABL fusion gene detection FISH Probe (the "Leukemia BCR/ABL FISH Probe") from the State Food and Drug Administration of China (the "SFDA").

The Leukemia BCR/ABL FISH Probe is a molecular diagnostic test kit that uses DNA probes for accurate detection of Philadelphia translocation, which is a specific chromosomal abnormality associated with chronic myelogenous leukemia ("CML"), acute lymphoblastic leukemia ("ALL") and acute myelogenous leukemia ("AML"). Philadelphia translocation is the result of a reciprocal translocation between chromosomes 9 and 22. The translocation results in the presence of a fusion gene which is created by juxtapositioning of a part of the breakpoint cluster region ("BCR") gene from chromosome 22 to the Abelson ("ABL") gene on chromosome 9. CML, ALL and AML are some of the most common types of leukemia, and detecting Philadelphia translocation is a critical diagnosis and prognosis guidance for selecting different treatment protocols for patients with CML, ALL and AML.

As of today, the Company has received SFDA approvals for all the major FISH probes that the Company acquired as part of the FISH business in March 2007, which include HER-2 FISH Probe, Prenatal FISH Probe, Cervical Cancer FISH Probe, Bladder Cancer FISH Probe and Leukemia BCR/ABL FISH Probe. The FISH probes that the Company developed after its acquisition of the FISH business in March 2007, such as the EGFR molecular diagnostic kits, Prostate Cancer FISH Probe, Lymphoma FISH Probe, Sarcoma FISH Probe and FISH probes related to other forms of leukemia, are either in the clinical trial stage or under SFDA review.

"We believe we have become a leading developer and manufacturer of FISH probes in China with the most comprehensive FISH probes for clinical screening, diagnosis and prognosis," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company. "We believe our FISH probes will continue to drive a healthy growth for our company by generating sustainable and recurring revenue. We are also confident that our newly developed FISH probes will be approved by the SFDA in the future on a timely basis."

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic (IVD) products using Enhanced Chemiluminescence (ECLIA) technology, Fluorescent in situ Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology to detect and monitor various diseases and disorders. For more information, please visit http://www.chinameditech.com/ .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

For more information, please contact:

Winnie Yam Tel: [phone] Email:

DATASOURCE: China Medical Technologies, Inc.


CONTACT: Winnie Yam, [phone], or


Web site: http://www.chinameditech.com/

[TheBunny]

About three and a half years ago I got a newsletter from a "Mr. Soussan" who was calling this company a "10 Banger". I got in at around $24.00 and out at about $20.
And I didn't look back and this sled any longer.
Yea...a 10 banger! HAHAHAHA!!!!

-Bunny-

[stockmarketgod]

dang i should have taken that $16.7 sold yesterday at $18

[juxtaposezen]

China Medical Technologies Announces Change of Independent Auditors

BEIJING, Aug. 7 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced the appointment of PricewaterhouseCoopers ("PwC") as the Company's independent registered public accounting firm. PwC replaces the Company's previous independent auditors, KPMG.

The appointment of PwC in replacement of KPMG has been approved by the Company's Audit Committee and the Board of Directors. Upon the appointment, PwC will commence the annual audit work and is working with the Company and KPMG to ensure a seamless transition. PwC has communicated with the Company's Audit Committee and the independent law firm engaged by the Audit Committee regarding the recent independent internal investigation before accepting this appointment. The Company expects to meet the deadline of filing its annual report on Form 20-F for the fiscal year ended March 31, 2009 before September 30, 2009.

"We would like to thank KPMG for their dedicated service over the past five years," said Mr. Sam Tsang, Chief Financial Officer of the Company. "However, we believe that PwC will provide our shareholders with the best combination of cost and quality going forward. We also expect that PwC will provide fresh insights to the Company to enhance our internal controls over financial reporting. We look forward to working with the PwC team."

The Company and KPMG have not had any disagreement on matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedures for which disagreement, if not resolved to the satisfaction of KPMG, would have caused KPMG to make reference to the subject matter of the disagreement in connection with its report on the Company's consolidated financial statements.

[juxtaposezen]

5-Star Stocks Poised to Pop: China Medical

By Brian D. Pacampara
October 6, 2009

Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health-care equipment maker China Medical Technologies (Nasdaq: CMED) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at China Medical's business and see what CAPS investors are saying about the stock right now.

China Medical facts

Headquarters (Founded)


Beijing, China (1999)

Market Cap


$514 million

Industry


Health-care equipment

Trailing-12-Month Revenue


$128 million

Management


Founder/CEO Xiaodong Wu

CFO Takyung Tsang

Return on Equity (Average, Past 3 Years)


15.4%

Cash / Debt


$226.5 million / $414.7 million

Dividend Yield


3.5%

Competitors


Johnson & Johnson (NYSE: JNJ)

Abbott Labs (NYSE: ABT)

CAPS Members Bullish on CMED Also Bullish on


Vale (NYSE: VALE)

Suntech Power (NYSE: STP)

CAPS Members Bearish on CMED Also Bearish on


China Mobile (NYSE: CHL)

China Finance Online (Nasdaq: JRJC)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 99% of the 461 All-Star members who have rated China Medical believe the stock will outperform the S&P 500 going forward. These bulls include mrindependent and TSIF, both of whom are ranked in the top 2% of our community.

Just last week, mrindependent tapped the stock as a cheap way to play some healthy tailwinds:

Despite remarkable technology and remarkable historic profitability and sales, China Medical Technologies is available for less than 7 times forward earnings and less than 2 times book value. [Jim Jubak] claims the Chinese government is trying to expand the country's health care system. This company should benefit from that policy.

In an earlier pitch, TSIF also diagnosed the situation:

Strong medical company in one of the fastest growing markets in the world. Medical procedures that appeal strongly to the small, but growing percent of Chinese affluent consumers. [In vitro diagnostics] in particular are very valuable in this market. ... If they lock into anything they can get approved in the USA market they will really grow, until then the growth potential, low P/E, strong margin, decent cash flow, and debt, (taken in context), make them a strong play.

http://www.fool.com/investing/international/2009/10/06/5-star-stocks-poised-to-pop-china-medical.aspx?source=itxsitmot0000001

[juxtaposezen]

Health care reform is an even bigger deal in China–and it will change the way to invest in that country
posted on September 29, 2009 at 8:30 am

Health care spending has doubled from 2002 to 2007.

Tens of millions of people aren’t covered by any health insurance and as a result of the global economic crisis and the consequent economic slowdown millions who had insurance have lost it.

Despite the rise in health care spending the population isn’t getting any healthier. Infant mortality rates, which had steadily declined since World War II, have plateau-ed. Diseases once under control have re-emerged.

And too many people live in fear that they’ve only one illness away from poverty.

Yep, things sure are bad…in China. So bad that in January the Beijing government announced a plan to spend $124 billion by 2011 to provide some form of health insurance to 90% of the population.

That’s a huge amount of money. The dollars being thrown around in our own healthcare debate seem much larger—the draft bill now being debated in the Senate Finance Committee carried a price tag of $856 billion when first introduced by Senator and committee chair Max Baucus (D-MONT). But that’s what adding coverage for the 30 million uninsured in the United States would cost over 10 years. At $124 billion for two years the Chinese price tag is impressively large.

Especially if you remember that China is still a relatively poor country. U.S. GDP (gross domestic product) hit $14.3 trillion in 2008, estimates the CIA World Factbook. Depending on how you adjust for China’s undervalued currency, the CIA World Factbook puts the size of China’s economy at either just $4. 4 trillion (at the official exchange rate) or $7 trillion at what’s called purchasing power parity. (Purchasing power parity attempts to adjust official figures to take account of what people in different countries actually pay for the same goods and services.)

Either way you look at it—whether China’s 1,340 million people live in an economy half the size of the U.S. economy inhabited by 310 million people or one just one-third the size–spending $60 billion a year to improve health care in China has the potential to be revolutionary.

And I think it will be exactly that. Especially if it is, as I think likely, just the first wave of government spending in areas such as health care, education, retirement pensions. We are looking at the beginning of revolutionary change in the Chinese economy.

And for investors that revolution will totally change how to make money in China.

Let me explain what’s so revolutionary about spending $124 billion over two years.

The goals of the plan seem modest enough. The government wants to extend some form of health insurance to 90% of the Chinese population. “Some form” is the key. Each person covered would get an annual subsidy worth about $17 beginning in 2010. Medicines would be covered by the insurance. Some of the money would go to improving health centers in rural areas and efforts would be made to reform the operation of public hospitals.

Now $17 a year per person doesn’t seem like much and indeed it’s not in the developed economies of the world. In rural China it’s a much bigger deal. Especially in rural China, which is, on average, much poorer than the urban areas.

In the first quarter of 2009, according to a nationwide government survey, the average household in rural China showed an annual income of $237 at official exchange rates. Rural households average 4.5 people. (Or at least they did in 1995, which is the most recent data I can find.) In a household of four people the new plan would provide an annual budget of $68 a year. That’s a big percentage on a household income of $237.

The effect though is even greater if you look at the way that the China’s health care system works at present. Everything and I mean everything requires a cash payment from the minute you walk through the door.

I’m going to take a few details from a description of a hospital visit by Bill Siggins, who had surgery in a Chinese hospital to remove his appendix. (You can read the complete account here http://opinion.globaltimes.cn/foreign-view/2009-09/466072.html )

For charge—10 Yuan, about $1.40, to register. Then after a preliminary diagnosis, tests to confirm the diagnosis. Total cost of that $100. Fortunately for Siggins an operating room was available—but it required a $730 deposit. In recovery a thermometer cost another $1.40. Patients and their families are supposed to provide things like a bowl spoon, towel and soap. Food tickets for meals cost about $2.20. (The system reminds me a bit of the last flight I took on a low-cost airline in Europe.)

This account doesn’t take us down into the pharmacy, which in many ways is a much more wrenching economic experience than the hospital itself. With the end of much government support for the hospitals, the pharmacies attached to hospitals have become major profit centers. Pharmacies are allowed to charge a 15% markup over the wholesale price of drugs.

That doesn’t seem like much. But pharmaceutical sales provided 43% of revenue at China’s general hospitals in 2005, according to a 2009 paper by Meredith Wen, “Averting Crisis: A Path Forward for China’s Healthcare System.” (To read the entire paper follow this link http://74.125.93.132/search?q=cache:UUSNgeo9twsJ:www.carnegieendowment.org/files/China_Healthcare_System_Full_Text.pdf+china+health+care+JANuary&cd=9&hl=en&ct=clnk&gl=us ). In that same year government funding provided must 7.4% of general hospital revenue. That figure had been 10.2% in 2002.

Siggins is very positive about the care he received—and frankly it sounds remarkably good in comparison to much of the developing world and to many places in the developed world, including some in the United States. But that’s not my point.

Think about living on a household income of $237 a year and knowing that a thing like an infected appendix could bankrupt you. And that without ready money–$100 or so—you can’t get a diagnosis or tests.

What would you do? If you live in China, you save like you’re life depends upon it. Because it does.

Do you really wonder why China’s savings rate is something like 40% (It could be as low as 30% or as high as 50%. In comparison, the Great Recession, which has caused U.S. consumers to save more, has driven the U.S. savings rate up to 4.2% in July, according to the St. Louis Federal Reserve.

But it’s not just the health care system that works—or doesn’t work for many people—this way. Most Chinese workers now don’t have meaningful retirement plans through work or the government. Many Chinese—certainly the 200 million or so migrant workers who in good times staff China’s export industries but who never get to be official residents of the city where they work—have to pay out of pocket to educate their kids.

It’s actually remarkable that the saving rate in China is as low as 40%.

The government has known about this problem of social insecurity for years. It is a completely predictable result of breaking the iron rice bowl, the sustain of government provided social services that formed the basis of Chinese society until the introduction of it’s all right to get rich economics by Deng Xiaoping.

But the decision to devote $124 billion to improving health care and providing a minimal level of health insurance is a remarkable sign that the government actually intends to do something about social insecurity in China.

And the leaders in Beijing are also moving to put money into education and pensions.

If there’s one thing we should have learned by now in the United States, it’s that once you create an entitlement—like Social Security or the Medicare drug benefit—it’s very, very hard to dis-create it. The Beijing leadership can indeed reverse course more easily than the U.S.Congress or President can—there are some advantages in not running for re-election—but it looks like the entitlement genie is out of the bottle in China for number of years to come.

What does that mean for those of us who constantly search for ways to invest in China?

It argues strongly that we should stop concentrating on the infrastructure and heavy industry, and export company stock plays that have had such a high profile in China’s recent development.

And that we should start looking, first, at the companies such as Ping An Insurance (PNGAY) or China Medical Technologies (CMED) that will be direct beneficiaries of more government spending on social services.

And second at companies that will be the future beneficiaries of a Chinese consumer who isn’t scared silly into saving 40% a year. Companies such as Ctrip.com (CTRP), an Internet travel company.

I wouldn’t rush out and buy these companies or any other name you can think of that today. The Chinese stock market is ludicrously expensive at the moment. That will fix itself. Chinese stocks are incredibly volatile and lower prices will come to he or she who waits.

And you’re not in any hurry. This revolution in China’s economy is just getting started and it has a long way to run.

http://jubakpicks.com/2009/09/29/health-care-reform-is-an-even-bigger-deal-in-china-and-it-will-change-the-way-to-invest-in-that-country/

[juxtaposezen]

Front-Month Call Players Flock to China Medical Technologies, Inc. (CMED)
9/28/2009 11:36 AM

China Medical Technologies, Inc. (CMED: sentiment, chart, options) was a favorite target among call traders on Friday, with single-session volume nearly six times the norm. More specifically, the China-based medical device maker saw roughly 11,800 calls cross the tape, compared to its average daily volume of fewer than 2,100 contracts.

The in-the-money October 15 and October 12.50 calls were most active, as a plethora of traders initiated ex-dividend plays on CMED. The October 15 call saw 8,400 contracts change hands, while the October 12.50 call saw 2,400 contracts traded.

Checking in on CMED's sentiment backdrop, it appears that near-term option traders are rather wary of the stock. The security's Schaeffer's put/call open interest ratio (SOIR) of 0.89 rests in the 70th annual percentile, suggesting that short-term option speculators have been more bearishly biased only 30% of the time during the past year. On that same note, the stock has garnered the attention of only three analysts, according to Zacks, with all issuing lukewarm "hold" ratings.

Technically speaking, it's not difficult to see why the Street is somewhat skeptical of CMED. The equity has surrendered 13.6% since the start of 2009, and has underperformed the broader S&P 500 Index (SPX) by 24.5% during the past 60 trading sessions. At last check, the security has backpedaled 30 cents, or 1.7%, to hang out in the $17.20 region.

[juxtaposezen]

Ibox updated. eom

[peewee]

Thanks for that info...will post to my longterm buddyd !
link in siggy

[juxtaposezen]

Institutional buyers are moving in:

Norges Bank filed a 13d with the sec disclosing that they have purchased 5.07% of CMED ADS based on 32,106,666 American Depositary Receipts issued..


http://www.sec.gov/Archives/edgar/data/1326059/000137417009000066/efc9-1809_formsc13g.txt

[peewee]

Good move !

[peewee]

[juxtaposezen]

Picked up some March $20 calls. Should be ITM by soon when buyback starts.

[juxtaposezen]

Up on a very down Market morning. eom

[peewee]

Thanks you !

[juxtaposezen]

Street Applauds China Med's Planned Share Buyback

China Medical Technologies (NSDQ: CMED) announced a $30 million share buyback program. The program will begin on October 1 and run for one year. China Medical is not obligated to spend the entire $30 million amount, and the release said the company may amend the program at any time.

Don’t worry about whether China Medical can afford the $30 million. At the end of its June quarter, the company reported a cash balance of $227 million, and its current market capitalization is $512 million, so the buyback represents only about 6% of the outstanding shares.

China Medical, an in-vitro diagnostic (IVD) devices company, currently focuses on three platforms: Enhanced Chemiluminescence (ECLIA) technology, Fluorescent in situ Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology.

The street applauded the buyback program by sending China Medical’s shares 89 cents higher to $15.91, a gain of 6%. Volume was slightly heavier than normal.

http://seekingalpha.com/article/162319-street-applauds-china-med-s-planned-share-buyback

[peewee]

[juxtaposezen]

This looks like the turnaround point here off of a double bottom, way undervalued. Tiny float now even smaller. Shorts don't like to pay dividends. Nice all around.

[peewee]

BUYBACKS + DIVI !!!

[ZoZoStockWatch]

[LGL8054]

Inider buys
Chen Zhong (Chief Technology Officer) 5,000 12.81 $64,050 2009-03-05
Wu Xiaodong (Chief Executive Officer) 100,000 13.30 $1,330,000 2009-03-04
Wu Xiaodong (Chief Executive Officer) 50,000 12.61 $630,500 2009-03-05
Wu Xiaodong (Chief Executive Officer) 50,000 12.57 $628,500 2009-03-06

[LGL8054]

Officer buy in
CMED China Medical Technologies, Inc. Chen Zhong (Chief Technology Officer) 5,000 shares @ $12.81 , total value 64,050 2009-03-05

[IPO$]

whay is CMED net income now?

[grantg2]

China Medical Technologies to Announce 4QFY2007 Financial Results,
Declare Annual Cash Dividend and Provide FY2008 Annual Targets on June 12, 2008
Friday 04/11/2008 7:30 AM ET - Pr Newswire

China Medical Technologies, Inc. (the ''Company'') (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products and high intensity focused ultrasound tumor therapy systems, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended March 31, 2008 (''FY2007''), declare annual cash dividend for FY2007 and provide annual targets for the fiscal year ending March 31, 2009 (''FY2008'') before the U.S. market opens on June 12, 2008. The Company's fiscal year ends on March 31. The Company's management will host an earnings conference call at 8:00 a.m., Eastern Time on the same day of the earnings announcement (8:00 p.m. Beijing/Hong Kong time).

Conference Call
The dial-in details for the live conference call are as follows:

-- U.S. Toll Free Number 1-800-260-8140
-- International dial-in number 1-617-614-3672
Passcode: CMEDCALL.

A live webcast of the conference call will be available on http://ir.chinameditech.com .

A replay of this webcast will be available for one month on this website.

A telephone replay of the call will be available after the conclusion of the conference call through 10:00 a.m. Eastern Time on June 13, 2008. The dial-in details for the replay are as follows:

-- U.S. Toll Free Number 1-888-286-8010
-- International dial-in number 1-617-801-6888
Passcode 52979476

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit http://www.chinameditech.com .

For more information, please contact:

Winnie Yam
Tel: [phone]
Email: [e-mail]

SOURCE China Medical Technologies, Inc.

http://www.chinameditech.com

[grantg2]

China Medical Technologies Completed the Development of Prostate Cancer FISH Reagent


BEIJING, April 3, 2008 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (NASDAQ:CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products and high intensity focused ultrasound tumor therapy systems, today announced the completion of development of the Prostate Cancer FISH Detection Kit (the "Kit"), a prostate cancer-specific molecular diagnostic test based on the Fluorescent in situ Hybridization ("FISH") technology. The Company expects to launch the Kit in July 2008.

The Kit is designed to detect TMPRSS2 and ETS gene fusions in prostate pathological tissues. Dysregulation of ETS family members through fusions with TMPRSS2 are implicated as cancer-causing gene rearrangements in prostate cancer, which can aid in the detection of early prostate cancer. The Kit consists of three dual-color probe sets, namely TMPRSS2/ETV1 probes, TMPRSS2/ERG probes and TMPRSS2/ETV4 probes. Studies have shown that TMPRSS2/ETS gene fusions occur in approximately 80 percent of prostate cancer cases, indicating that the application of TMPRSS2/ETS gene fusions as specific biomarkers can significantly increase the sensitivity for prostate cancer diagnosis. In addition, it has been reported that the TMPRSS2/ERG fusion may have prognostic significance.

"The successful development of the Kit is a milestone in expanding our FISH reagent portfolio, which represents the first significant product developed by our researchers since the FISH acquisition in 2007," said Mr. Xiaodong Wu, Chairman and CEO of the Company. "Our FISH business has become an important growth driver of the Company and we believe the continual launch of new FISH reagents with huge potential of diagnostic application will drive the growth of our recurring reagent business rapidly."

Prostate cancer is one of the most frequent cancers among men in China and many other countries. In China, prostate-related diseases affect about 60-70% of men over 60 years of age of which the population is about 80 million. Among them, patients with prostate enlargement who need surgical therapy have the opportunity to benefit from the use of the Kit to resolve the diagnosis of prostate cancer.

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit http://www.chinameditech.com/ .

For more information, please contact:

China Medical Technologies, Inc.

Sam Tsang Tel: [phone] Email:

DATASOURCE: China Medical Technologies, Inc.


CONTACT: Sam Tsang of China Medical Technologies, Inc., [phone],

or


Web site: http://www.chinameditech.com/

[grantg2]

China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents


BEIJING, March 24 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (NASDAQ:CMED), a leading China-based medical device company that develops, manufactures and markets advanced in- vitro diagnostic ("IVD") products and high intensity focused ultrasound tumor therapy systems, today announces that the Company receives the Conformite Europeenne Mark ("CE Mark") for its two semi-automatic ECLIA analyzers and 15 reagents.

Under the In-Vitro Diagnostic Directive ("IVDD") of the European Union ("EU"), products must meet regulatory requirements in order to qualify for sales and distributions in the EU. A CE Mark indicates that a product complies with the EU regulatory requirements. The Company receives the CE Mark for its two semi-automatic ECLIA analyzers and 15 reagents, including thyroid disorders, diabetes and tumor marker reagents.

"The CE Mark demonstrates that our products meet the IVDD requirements," said Mr. Xiaodong Wu, Chairman and CEO of the Company. "It not only allows us access to new markets but also strengthens our leading position in the advanced IVD market in China."

ECLIA system is a closed IVD system including an analyzer and reagents that are used to detect and quantify particular antibodies or antigens for the diagnosis and analysis of various diseases and disorders. The Company will continue to work on receiving CE Mark for its other ECLIA reagents.

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit http://www.chinameditech.com/ .

For more information, please contact:

China Medical Technologies, Inc.

Winnie Fan Email:

DATASOURCE: China Medical Technologies, Inc.


CONTACT: Winnie Fan of China Medical Technologies, Inc., [phone],

or


Web Site: http://www.chinameditech.com/

[grantg2]

Earnings Numbers Out......


February 28, 2008 5:17 PM EST
China Medical Technologies, Inc. (Nasdaq: CMED) reports Q3 adj-EPS of $0.60, 14 cents better than the analyst estimate of $0.46.

Revenues for the quarter were $36.3 million, versus the consensus of $36.55 million.

Reaffirms FY08 EPS guidance of $2.03-$2.07,
versus the consensus of $1.52.

Revs are expected to be $117.9-$121.3 million, versus $125.61 million.

[grantg2]

China Medical Technologies Completes Acquisition of BBE
PR NEWSWIRE
Posted: 2008-01-08 05:03:31
BEIJING, Jan. 8 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in- vitro diagnostic ("IVD") products and high intensity focused ultrasound tumor therapy system, today announced that it has completed its previously announced acquisition (the "Acquisition") of the entire interest in Beijing Bio-Ekon Biotechnology Co., Ltd ("BBE"), a fast-growing ECLIA player in China. The Acquisition is expected to strengthen the Company's leading position in advanced IVD market in China.

The Company expects the Acquisition to be accretive immediately from the current quarter ending March 31, 2008, resulting in increases in both revenues and adjusted non-GAAP net income.

About China Medical Technologies

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced IVD products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit http://www.chinameditech.com .

About Beijing Bio-Ekon Biotechnology Co., Ltd.

Founded in 1999, BBE commenced business in selling ELISA IVD products in China. In 2006, BBE launched its first semi-automatic ECLIA analyzer and related reagents upon receiving approval from the State Food and Drug Administration. BBE has sales offices in Beijing, Guangzhou, Wuhan, Qingdao and Chengdu to conduct direct sales and manage distributors in selling its products to over 800 hospitals in China.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the expectations of BBE's contributions to the Company's leading position in advanced IVD market in China and its future financial results in this press release contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, including risks related to the ability of the Company to successfully integrate BBE's businesses into the Company's existing operations in a timely manner and the successful launch and market acceptance of BBE's future products in China. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.


For more information, please contact:Sam Tsang
China Medical Technologies, Inc.
Tel: [phone]
Email: [e-mail]
SOURCE China Medical Technologies, Inc.

[grantg2]

More specific details to listen to the call live...

China Medical Technologies to Announce Financial Results for the Third Quarter Ended December 31, 2007 on February 28, 2008
PR NEWSWIRE
Posted: 2008-01-29 05:03:38
BEIJING, Jan. 29 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in- vitro diagnostic products and high intensity focused ultrasound tumor therapy systems, today announces that it will report its unaudited financial results for the third quarter ended December 31, 2007 ("3Q FY2007") after the U.S. market closes on February 28, 2008. The Company's 2007 fiscal year ends on March 31, 2008. The Company's management will host an earnings conference call at 8:00 p.m., Eastern Time on the same day of the earnings announcement (9:00 a.m. on February 29, 2008 Beijing/Hong Kong time).


Conference Call
The dial-in details for the live conference call are as follows:-- U.S. Toll Free Number 1-866-700-7101
-- International dial-in number 1-617-213-8837
Passcode: CMEDCALL.

A live webcast of the conference call will be available on http://ir.chinameditech.com.

A replay of this webcast will be available for one month on this website.

A telephone replay of the call will be available after the conclusion of the conference call through 10:00 p.m. Eastern Time on February 29, 2008. The dial-in details for the replay are as follows:


-- U.S. Toll Free Number 1-888-286-8010
-- International dial-in number 1-617-801-6888
Passcode: 87116521

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit http://www.chinameditech.com .


For more information, please contact:China Medical Technologies, Inc.
Winnie Fan
Tel: [phone]
Email: [e-mail]
SOURCE China Medical Technologies, Inc.

[grantg2]

China Medical Technologies, Inc.
Earnings Conference Call (Q3 2007)

Scheduled to start Thu, Feb 28, 2008, 8:00 pm Eastern

After the event has finished, the audio will be available
from this page until Sun, Mar 1, 2009

http://biz.yahoo.com/cc/9/89269.html

[grantg2]

As of January 4, 2008....

You should see CMED
China Medical Technology hasn't done as well as its mainland peer but, with an 83% gain over the past year, it is still a massive market-beater. Here's why:

Revenue (In Chinese Renminbi)
FY 2007 547.0
FY 2006 371.8
FY 2005 217.8
FY 2004 110.8
Source: Capital IQ, a division of Standard & Poor's.
That's three years of 70% average annual growth!

Some investors see more gains on the way, thanks to the company's innovations in cancer treatment. Here's how CAPS All-Star kwfisher put it in March:

... HIFU technology approval for use in the U.S. and other large foreign markets is the big potential payoff, but these approvals are not necessary for the stock to be a compelling value today. Its diagnostics systems appear to provide a steady and substantial source of growth on their own.

Indeed, according to Capital IQ, China Medical trades for 26 times this year's earnings for a low 0.87 PEG ratio. Will Danoff of the Fidelity Contrafund (FCNTX) apparently believes that's too cheap. He was a buyer as of October.

[grantg2]

Must be the reason for the nice recovery in PPS over the last week...

CMED is a diversified company that has been doing very well the last few years...

and should continue to do so IMO...

(However, when I checked the link provided, nothing about CMED was displayed... could you repost a short summary of what was intended to be shown... or cut and paste it? Thanks)

[grantg2]

NEWS & no fortune cookie...LOL

China Medical Technologies IDE Application Approved
Friday 07/20/2007 6:31 AM ET - SinoCast
The Chinese medical device company China Medical Technologies, Inc. (Nasdaq: CMED) on July 16, 2007 announced its winning of the approval from the US Food and Drug Administration conditionally, able to excise the tumor of some patients with pancreatic cancer safely in clinic practice by making use of HIFU (High Intensity Focused Ultrasound) system.

As known, this clinic trial is expected to be carried out at the medical care center of the University of Washington in Seattle city of the US, but it also needs the approval from the Institutional Review Board erenow.

The Chinese company's CEO Wu Xiaodong aired that it was the company's milestone as expanding the presence in the US HIFU tumor cure sector in prophase period.

From stocknews.com.cn, Page 1, Thursday, July 19, 2007 [e-mail]

[grantg2]

Stock is doing well & no one here...

no updates to the iBox...

no news or comments being posted...

and the moderator is MIA!!!!!!!!!!!!

What a shame!

JMO... go placidly and grow, CMED!

[grantg2]

HELLOOOOOO... where is the moderator...

why are YOU not posting the news! Why no posts on this company doing so well since last year????

Here is a RB post from last JULY (and my current reply):

By: jp_pav00 (CEMENT, jp??? you lost if you sold!)
14 Jun 2006, 06:09 PM EDT
Msg. 149 of 171
Jump to msg. #
They should change the symbol fron CMED to CEMENT.
- - - - -

This is a second reply to this post by me... first was back when I started looking at CMED and bought at 17-18 range!

Obviously jp_pav00 is hyperactive and does not have the patience to let an innovative solid company move forward on the many fronts this company is involved in!

31 on an 18 investment is not TOO SHABBY (72%) even IF it were time to sell and move on... and this company as a stock play is just beginning!

It's pricier now than it was, but it is going MUCH HIGHER in the years to come... buy now and buy again later on... then HOLD for a legacy stock in your portfolio!

Anyone hear of GE? GE owns about a 17% stake in this company! I don't know whether GE is advising them on growing this company, or NOT. Who cares, this is going to be a company that could be the GE of China.

JMO...

[grantg2]

Some nice up movement on the release of news about the Downs Syndrome tests CMED involved with developing! This company just slowly moves along looking better and better as the months pass.

I would expect some traders to sell off again and knock it back down, though!

http://new.quote.com/stocks/story.action?id=BIZ354b1143

http://new.quote.com/stocks/story.action?id=XFN354h0782

http://new.quote.com/stocks/story.action?id=RTT612201257001786

I do not know why the news was released on two different days, but all three of these PRs are about the new reagents/test.

[Fortune_Cookie]

News - China Medical Forms Strategic Partnership with Itochu's Subsidiary, Century Medical, to Develop HIFU Distribution in Japan


2006-12-05 07:30 ET - News Release


Company Website: http://www.chinameditech.com
BEIJING -- (Business Wire)

China Medical Technologies, Inc. (the “Company”) (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets high intensity focused ultrasound (“HIFU”) products and advanced in-vitro diagnostic systems, today announced that it has entered into an exclusive distribution agreement with Century Medical, Inc., a leading Japan-based medical device distributor wholly owned by Itochu Corporation (“Itochu”) (TSE: 8001), to distribute HIFU tumor therapy systems in Japan.

According to the terms of the agreement, China Medical’s HIFU tumor therapy systems will be exclusively marketed and distributed by Century Medical in Japan after the designated marketing authorization approval, or “shonin,” is obtained. Century Medical will work together with China Medical to obtain the shonin from the Japanese Ministry of Health, Labor and Welfare (the “MHLW”). China Medical intends to use the data from the clinical trials to be conducted in the U.S. to apply for the shonin and will bear all relevant costs.

Itochu is a major trading and investment conglomerate in Japan that was founded in 1858. Its wholly owned subsidiary, Century Medical, has over 30 years of experience in the distribution of advanced medical devices, including extensive experience in import licensing, importation, inventory support, sales and marketing, and customer service. Century Medical’s product offering includes surgical products, interventional peripheral and neuron-radiology, cardiology and cardiovascular devices.

"We are very pleased to appoint Century Medical as the exclusive distributor of our HIFU tumor therapy system in Japan upon obtaining the shonin," commented Mr. Xiaodong Wu, Chairman and CEO of China Medical. “We believe this partnership marks an important milestone for China Medical as it takes advantage of the strengths of both companies and sets a foundation to support the long term growth of our business by expanding into one of the world’s largest medical device markets. In addition, we will continue to explore other cooperation opportunities with Century Medical for medical device distribution in Japan.”

“The forming of our strategic partnership with China Medical is based on a series of detailed and thorough evaluations. We look forward to working closely with China Medical to pave the way for our execution of a comprehensive marketing and distribution plan for the HIFU tumor therapy system in Japan. We believe China Medical’s HIFU tumor therapy system will bring Japanese patients substantial benefits given its non-invasive characteristics,” stated Mr. Toshio Konishi, President and CEO of Century Medical.

About China Medical Technologies

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets products using high intensity focused ultrasound for the treatment of solid cancers and benign tumors and advanced in-vitro diagnostics products using enhanced chemiluminescence technology, to detect and monitor various diseases and disorders. For more information, please visit our website at www.chinameditech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,”“expects,”“anticipates,”“future,”“intends,”“plans,”“believes,”“estimates” and similar statements. Among other things, the Company’s expectation to obtain the shonin approval and to sell its HIFU tumor therapy system in Japan through Century Medical contains forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in China Medical’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. China Medical does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contacts:

China Medical Technologies, Inc.
Ms. Winnie Fan, (86) 10 6530 8833
[e-mail]
or
Christensen
Mr. Tip Fleming, (1) 917-412-3333
[e-mail]

Source: China Medical Technologies, Inc.

[Fortune_Cookie]

News - China Medical Technologies, Inc. Closes Offering of US$150 Million Convertible Senior Subordinated Notes


2006-11-21 12:25 ET - News Release


Company Website: http://www.chinameditech.com
BEIJING -- (Business Wire)

China Medical Technologies, Inc. (Nasdaq: CMED) today announced the closing of the offering of US$150 million principal amount of 3.5% Convertible Senior Subordinated Notes due 2011 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of notes sold reflects the exercise in full by the initial purchaser of its option to purchase up to an additional US$25 million aggregate principal amount of the notes to cover over-allotments.

This press release does not constitute an offer to sell or a solicitation of an offer to buy securities. Any offers of the securities will be made only by means of a private offering memorandum. The securities offered have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About China Medical

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets products using high intensity focused ultrasound for the treatment of solid cancers and benign tumors and advanced in-vitro diagnostics products using enhanced chemiluminescence technology, to detect and monitor various diseases and disorders. For more information, please visit our website at www.chinameditech.com.

Contacts:

China Medical Technologies, Inc.
Winnie Fan, 86 10 6530 8833
Email: [e-mail]
or
Christensen
Tip Fleming, 1 917 412 3333
Email: [e-mail]

Source: China Medical Technologies, Inc.

[grantg2]

Long in this stock at just under 20 & looking for slow and steady progress into the indefinite future.

The focussed ultrasound is a BIG DEAL... the rest of the company's product line is nice & the recent HIV screens and acoustic devices areas hold potential... BUT...

IMHO the BIG DEAL is the ultrasound system...AND that is what has GE into approx. a 15% ownership of this stock!!!!!!!!!

That has not been mentioned on this board so far as I've read... and as a retired service engineer in the medical field, I can tell you that IF GE brings this technology to the world market under their label in a joint venture with CMED...

well, we are talking revolutionary change in cancer treatments & megabucks in earnings! The US market will eat this product up... they will sell thousands of systems! Guess we will see in due time...

[Jethro Bodine1]

This one looks promising...we will see..earnings monday...

[Fortune_Cookie]

News: China Medical Technologies and the Chinese Academy of Sciences Institute of Acoustics Establish a Medical Research Laboratory to Develop Acoustic Medical Devices


2006-11-06 05:00 ET - News Release


Company Website: http://www.chinameditech.com
BEIJING -- (Business Wire)

China Medical Technologies, Inc. (the “Company”) (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets high intensity focused ultrasound products and advanced in-vitro diagnostic systems, today announced that the Company has entered into a 10-year collaboration agreement with the Chinese Academy of Sciences Institute of Acoustics (the “Institute”) to establish a medical research laboratory that is expected to be used as a platform for the development and commercialization of acoustic medical devices. The goal of this initiative is to enhance the Company’s research capabilities, expedite the development of new products as well as to expand the Company’s product range.

Under the terms of the agreement, China Medical will be responsible for all of the development costs and will in turn retain the intellectual property rights relating to these products. The Company expects to fund the laboratory on a project basis over the 10-year period. The potential and feasibility of each project will be thoroughly and cautiously assessed by the Company together with the Institute. The related budget of each project will be examined prior to entering into any capital commitments.

As a well-established research institution in China, the Institute has been engaged in a vast number of national research projects in acoustic and signal information analysis, and ultrasonic and linguistic acoustics since its founding in 1964. Its key achievements include over 400 established research results and over 300 national winning awards on the related subjects. This collaboration is expected to also help strengthen the Institute’s position in academic and clinical studies.

“We believe that this synergistic collaboration is an excellent strategy for the Company and underscores our commitment to broaden the scope of our acoustic and ultrasound technologies,” said Mr. Xiaodong Wu, Chairman and CEO. “We are encouraged by the many mutual benefits that this collaboration provides and believe that acoustic medical products have great potential to further improve the quality of human lives. Overall, we think this is a great opportunity for us to broaden and diversify our product offering in the medical device market in China while remaining firmly in an area that we know well, with partners we trust. We are now actively assessing the potential of a number of acoustic projects with the Institute, and we will continue to search for other opportunities in the market that will allow us to follow through on our stated goal of becoming the leading medical device company in China.”

Leveraging the existing acoustic technology and expertise of the Institute, China Medical aims to develop affordable acoustic medical devices that address the needs of patients, and the vast and untapped market potential that exists in China. The Company believes that its proven track record of developing high quality medical devices, strong distribution network, and well established commitment to controlling costs will allow the Company to benefit from the research and development of these innovations. The Company looks forward to disclosing specific product development plans once a thorough assessment has been completed.

About China Medical Technologies

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets products using high intensity focused ultrasound for the treatment of solid cancers and benign tumors and advanced in-vitro diagnostics products using enhanced chemiluminescence technology, to detect and monitor various diseases and disorders. For more information, please visit our website at www.chinameditech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,”“expects,”“anticipates,”“future,”“intends,”“plans,”“believes,”“estimates” and similar statements. Among other things, the Company’s expectation and strategy with respect to researching and developing the above mentioned acoustic medical devices with collaboration of the Institute contains forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in China Medical’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. China Medical does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contacts:

China Medical Technologies, Inc.
Ms. Winnie Fan, 86 10 6530 8833
[e-mail]
or
Christensen
Mr. Tip Fleming, 1 917 412 3333
[e-mail]


Source: China Medical Technologies

[Fortune_Cookie]

News: China Medical to Announce Second Quarter Unaudited Financial Results for the Fiscal Year Ending March 31, 2007 on November 13, 2006


2006-10-25 06:00 ET - News Release


Company Website: http://www.chinameditech.com
BEIJING -- (Business Wire)

China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets high intensity focused ultrasound tumor therapy systems and advanced in-vitro diagnostic systems, announced that it will release its unaudited financial results for the September quarter of the fiscal year ending March 31, 2007 (“2Q FY 2006”) after the U.S. market closes on Monday, November 13, 2006. The Company will host a conference call that day at 6:00 p.m. Eastern Time (7:00 a.m. Beijing/Hong Kong time on November 14, 2006), to discuss the results.

For the conference call, Mr. Sam Tsang, Chief Financial Officer, Mr. Charles Zhu, Vice President, and Ms. Winnie Fan, Senior Manager of Finance and Investor Relations will discuss the results and take questions.

OUTLOOK FOR FY2006

The Company maintains the outlook for FY2006. The estimated annual net revenues for FY2006 remains to be between RMB521 million (US$65.2 million) and RMB533 million (US$66.7 million) and annual net income for FY2006 remains to be between RMB263 million (US$32.9 million) and RMB271 million (US$33.9 million). Given the current outstanding shares of 27.36 million equivalent ADS, the estimated earnings per ADS is between RMB 9.61 (US$1.20) and RMB9.90 (US$1.24). For the convenience of readers, RMB amounts have been translated into U.S. dollars at the rate of RMB7.9943 to US$1.00.

CONFERENCE CALL

The dial-in details for the live conference call are as follows:

U.S. Toll Free Number +1.866.383.8108
International dial-in number +1.617.597.5343
Passcode CMEDCALL.

A live webcast of the conference call will be available on the investor relations section of the Company’s website at: www.chinameditech.com.

A replay of the webcast will be available for one month on this website.

A telephone replay of the call will be available after the conclusion of the conference call through 6:00 p.m. Eastern Time, November 14, 2006.

The dial-in details for the replay are as follows:

U.S. Toll Free Number +1.888.286.8010
International dial-in number +1.617.801.6888
Passcode 17516986.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the Company's expectations of projected annual results in this press release contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in China Medical's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. China Medical does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

About China Medical Technologies, Inc.

China Medical Technologies, Inc. is a China-based medical device company that develops, manufactures and markets products in China using HIFU, for the treatment of solid cancers and benign tumors. China Medical believes that it is a leader in the design and development of HIFU tumor therapy devices in China. In addition, China Medical believes that it is the first China-based company to offer an advanced in-vitro diagnostics system, or IVD system, using enhanced chemiluminescence, or ECLIA, technology to detect and monitor various diseases and disorders through laboratory evaluation and analysis of blood, urine or other body fluids.

Contacts:

China Medical Technologies, Inc.
Winnie Fan, 86 10 6530 8833
[e-mail]
or
Christensen
Tip Fleming, 1-917-412-3333
[e-mail]

Source: China Medical Technologies, Inc.

[Fortune_Cookie]

News: China Medical Technologies Successfully Develops Two HIV Diagnostic Reagents


2006-10-11 11:53 ET - News Release

The Research That Led to the Development of the Two HIV Diagnostic Reagents Was Chosen by the PRC Ministry of Health as One of Its Sponsored “Innovative Research Projects on AIDS Prevention and Treatment in 2006”


Company Website: http://www.chinameditech.com
BEIJING -- (Business Wire)

China Medical Technologies, Inc. (the “Company”) (NASDAQ: CMED), a leading China-based medical device company that develops, manufactures and markets high intensity focused ultrasound products and advanced in-vitro diagnostic systems, today announced that it has successfully completed the development of two HIV diagnostic reagents (the “HIV reagents”) using chemiluminescence immunoassay technology for both HIV initial screening and HIV definitive diagnosis. The PRC Ministry of Health has chosen the Company’s research that led to the development of the HIV reagents as one of its sponsored “innovative research projects on AIDS Prevention and Treatment in 2006”.

Currently, commonly-used HIV diagnostic tests in China include rapid screening technologies such as Enzyme-Linked ImmunoSorbent Assay (“ELISA”) for initial screening, and using other technologies with higher specificity such as Western Blot for definitive diagnosis after the initial screening.

There are approximately 3,800 accredited HIV initial screening labs and 57 Center for Disease Control (“CDC”) HIV definitive diagnostic labs in China. Positive HIV samples identified by the screening labs must be verified by one of the definitive diagnostic labs. The Company believes that the introduction of the HIV reagents will enable the screening labs to perform more accurate diagnosis in the future, which will help China further strengthen AIDS prevention and treatment efforts.

The Company recently submitted an application to register the reagents with the State Food and Drug Administration of China (the “SFDA”) after a large sample clinical trial had been completed. Under normal circumstances, the SFDA would take approximately 12 months to complete the approval process. The Company has been advised that its application for the HIV reagents is entitled to a fast track approval process and expects to obtain the relevant approval in less than 12 months.

About China Medical Technologies:

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets products using high intensity focused ultrasound for the treatment of solid cancers and benign tumors and advanced in-vitro diagnostics products using enhanced chemiluminescence technology, to detect and monitor various diseases and disorders. For more information, please visit our website at www.chinameditech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,”“expects,”“anticipates,”“future,”“intends,”“plans,”“believes,”“estimates” and similar statements. Among other things, The Company’s expectation to obtain relevant SFDA approval with respect to the HIV reagents in less than 12 months contains forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in China Medical’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. China Medical does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contacts:

China Medical Technologies, Inc.
Ms. Winnie Fan, (86) 10 65308833
[e-mail]
or
Christensen
Mr. Tip Fleming, (1) 917 4123333
[e-mail]

Source: China Medical Technologies, Inc.

[butterfly111]

The earlier decline not was just because of shorting, also because the expiry of IPO lockup around mid-Feb. (180 days after IPO). Other IPO shares will expire 360 days after IPO. 5.75 mil shares will be able to trade 180 days after March...

CMED is heavily manipulated (like STP) and it is easy to manipulate this type of low float stocks. It is now only for trading, not for holding. buy bet. 26-27, and sell bet. 30-31

[xZx]

b-fly, CMED has been trading very badly lately. i made a mint off that last run, but when i hopped back in a few days ago i got whipsawed like crazy. even though this is off the reg sho listing it seems the shorts are still playing CMED like a fiddle.

i consult this page daily: http://www.nasdaqtrader.com/ASPX/REGSHO.ASPX

I may grab a little more CMED again if we get some volume going. good luck!

[butterfly111]

I picked some CMED this morning, a little too early average at $27.3, but I think I will ok. Dippers coming in now, could end up green<g>

[xZx]

thank you for that, bfly.

[butterfly111]

Just make sure sell your longs by Aug./Sep. the lockup will be over for millions of IPO and secondary shares

[madrose1]

may have often traded CMED over here
http://www.investorshub.com/boards/board.asp?board_id=1125

feel free to add updates and comments .